GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October:

• H.C. Wainwright 4^th Annual NASH Investor Conference
  Monday, October 5, 2020 – 3:30 pm ET
  

• Guggenheim Securities’ 1^st Annual Vaccines & Infectious Diseases Day
  Monday, October 5, 2020 – 4:45 pm ET
  

The H.C. Wainwright presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events/Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.

Investor Contacts:

Stacey Jurchison	Ashley R. Robinson
Altimmune, Investor Relations	LifeSci Advisors, LLC
Phone: 410-474-8200	617-430-7577
sjurchison@altimmune.com	arr@lifesciadvisors.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.